Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia

Clinical Cancer Research

Volumn 19, Issue 11, 2013, Pages 2893-2904

  Ouillette, Peter ^a   Saiya Cork, Kamlai ^a   Seymour, Erlene ^a   Li, Cheng ^c   Shedden, Kerby ^b   Malek, Sami N ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CELL PROTEIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLAVOPIRIDOL; FLUDARABINE; IFOSFAMIDE; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; NOTCH1 RECEPTOR; OFATUMUMAB; PENTOSTATIN; PREDNISONE; PROTEIN P53; PROTEIN SF3B1; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL PROLIFERATION; CHROMOSOME DELETION; CHROMOSOME DELETION 11Q; CHROMOSOME DELETION 13Q14; CHROMOSOME DELETION 17P; CHRONIC LYMPHATIC LEUKEMIA; CLONAL EVOLUTION; EXON; FEMALE; GENE DOSAGE; GENE SEQUENCE; GENOME; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; LEUKEMIA RELAPSE; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURAL GENOMICS;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CLONAL EVOLUTION; DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; FEMALE; GENOMICS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; PHOSPHOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, NOTCH1; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84878411259     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0138     Document Type: Article

References (41)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-15.
2. Malek SN. The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia. Oncogene 2012 Sep 24. [Epub ahead of print].
3. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-7. (Pubitemid 29430399)
4. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-54. (Pubitemid 29430400)
5. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-6. (Pubitemid 32064784)
6. Kujawski L, Ouillette P, Erba H, Saddler C, Jakubowiak A, Kaminski M, et al. Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. Blood 2008;112:1993-2003.
7. Ouillette P, Collins R, Shakhan S, Li J, Peres E, Kujawski L, et al. Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood 2011;118:3051-61.
8. Malek S. Clinical utility of prognostic markers in chronic lymphocytic leukemia. ASCO Education Book 2010 2010:263-7.
9. Van Bockstaele F, Verhasselt B, Philippe J. Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev 2009;23:25-47.
10. Rassenti LZ, Jain S, Keating MJ, Wierda WG,Grever MR, Byrd JC, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008;112:1923-30.
11. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002;100:1177-84. (Pubitemid 34864269)
12. Landgren O, Albitar M, Ma W, Abbasi F, Hayes RB, Ghia P, et al. B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med 2009;360:659-67.
13. Zenz T, Habe S, Denzel T, Mohr J, Winkler D, Buhler A, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009;114:2589-97.
14. Shanafelt TD, Hanson C, Dewald GW, Witzig TE, LaPlant B, Abrahamzon J, et al. Karyotypeevolutionon fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression. J Clin Oncol 2008;26:e5-6.
15. Cavazzini F, Rizzotto L, Sofritti O, Daghia G, Cibien F, Martinelli S, et al. Clonal evolution including 14q32/IGH translocations in chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105 patients. Leuk Lymphoma 2012;53:83-8.
16. Knight SJ, Yau C, Clifford R, Timbs AT, Sadighi Akha E, Dreau HM, et al. Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia. Leukemia 2012;26:1564-75.
17. Stilgenbauer S, Sander S, Bullinger L, Benner A, Leupolt E, Winkler D, et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 2007;92:1242-5. (Pubitemid 350144184)
18. Braggio E, Kay NE, VanWier S, Tschumper RC, Smoley S, Eckel-Passow JE, et al. Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse. Leukemia 2012;26:1698-701.
19. Gunnarsson R, Mansouri L, Isaksson A, Goransson H, Cahill N, Jansson M, et al. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. Haematologica 2011;96:1161-9.
20. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-7. (Pubitemid 26189840)
21. Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, Li C. dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics 2004;20:1233-40. (Pubitemid 38807579)
22. Ross CW, Ouillette PD, Saddler CM, Shedden KA, Malek SN. Comprehensive analysis of copy number and allele status identifies multiple chromosome defects underlying follicular lymphoma pathogenesis. Clin Cancer Res 2007;13:4777-85. (Pubitemid 47294784)
23. Parkin B, Erba H, Ouillette P, Roulston D, Purkayastha A, Karp J, et al. Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. Blood 2010;116:4958-67.
24. Long J, Parkin B, Ouillette P, Bixby D, Shedden K, Erba H, et al. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood 2010;116:71-80.
25. Ouillette P, Erba H, Kujawski L, Kaminski M, Shedden K, Malek SN. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res 2008;68:1012-21. (Pubitemid 351272218)
26. Parker H, Rose-Zerilli MJ, Parker A, Chaplin T, Wade R, Gardiner A, et al. 13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia. Leukemia 2011;25:489-97.
27. Ouillette P, Collins R, Shakhan S, Li J, Li C, Shedden K, et al. The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia. Clin Cancer Res 2011;17:6778-90.
28. Pfeifer D, Pantic M, Skatulla I, Rawluk J, Kreutz C, Martens UM, et al. Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood 2007;109:1202-10. (Pubitemid 46220669)
29. Saddler C, Ouillette P, Kujawski L, Shangary S, Talpaz M, Kaminski M, et al. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 2008;111:1584-93. (Pubitemid 351213449)
30. Malcikova J, Smardova J, Rocnova L, Tichy B, Kuglik P, Vranova V, et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood 2009;114:5307-14.
31. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994;84:3148-57.
32. el Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R, et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993;82:3452-9. (Pubitemid 23356719)
33. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 1991;88:5413-7. (Pubitemid 21914755)
34. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475:101-5.
35. Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2011;44:47-52.
36. Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, Messina M, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011;118:6904-8.
37. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011;365:2497-506.
38. Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, Ma J, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011;208:1389-401.
39. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013;152:714-26.
40. Villamor N, Conde L, Martinez-Trillos A, Cazorla M, Navarro A, Bea S, et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia 2012 Dec 6. [Epub ahead of print].
41. Shedden K, Li Y, Ouillette P, Malek SN. Characteristics of chronic lymphocytic leukemia with somatically acquired mutations in NOTCH1 exon 34. Leukemia 2012;26:1108-10.